NCT06798376 Different Cycles of Neoadjuvant PD-1 Blockades + Chemotherapy for Advanced Gastric Cancer
| NCT ID | NCT06798376 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese PLA General Hospital |
| Condition | Gastric Adenocarcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2025-01-16 |
| Primary Completion | 2025-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2025-01-16 with a primary completion date of 2025-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to analyze the impact of different durations of neoadjuvant PD-1 inhibitor combined with chemotherapy on tumor regression and safety in patients with advanced gastric cancer. The main questions it aims to answer are: * Does the duration of neoadjuvant treatment influence tumor regression grading (TRG)? * How does treatment duration affect perioperative safety and clinical outcomes? Participants who have previously undergone neoadjuvant PD-1 inhibitor combined with chemotherapy followed by surgery as part of their routine medical care will have their clinical data retrospectively reviewed and analyzed.
Eligibility Criteria
Inclusion Criteria: * Non-bedridden patients aged 18-90 years; * Histologically confirmed gastric or gastroesophageal junction adenocarcinoma by biopsy; * Evaluated as resectable advanced gastric cancer via CT, MRI, or laparoscopic exploration; * No prior anti-tumor treatments such as chemotherapy, radiotherapy, or immunotherapy; * No history of other malignancies within the past 5 years; * Received at least one cycle of PD-1 inhibitor combined with chemotherapy preoperatively, with no restrictions on the specific PD-1 inhibitor or chemotherapeutic agents; * Underwent radical gastrectomy after neoadjuvant therapy; * No severe underlying diseases. Exclusion Criteria: * Incomplete or inaccessible clinical and pathological data; * Postoperative pathology confirming non-gastric or non-gastroesophageal junction adenocarcinoma; * Distant metastases present prior to treatment; * Concurrent diagnosis of other malignancies.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06798376 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Gastric Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06798376 currently recruiting?
Yes, NCT06798376 is actively recruiting participants. Contact the research team at wangxx301@outlook.com for enrollment information.
Where is the NCT06798376 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06798376 clinical trial?
NCT06798376 is sponsored by Chinese PLA General Hospital. The trial plans to enroll 300 participants.